Merck, Inc.
🇵🇭Philippines
Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)
Completed
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Biological: Infliximab
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2015-09-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 320
- Registration Number
- NCT00818168
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
Phase 1
Terminated
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 92
- Registration Number
- NCT00818259
Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)
Completed
- Conditions
- Crohn's Disease
- Interventions
- Biological: Remicade (infliximab)
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2015-09-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 148
- Registration Number
- NCT00818272
A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064)
Phase 1
Completed
- Conditions
- Muscle Anabolism
- First Posted Date
- 2009-01-05
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT00816712
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 395
- Registration Number
- NCT00813995
Biomarkers of Muscle Anabolism (MK-0000-082)
Phase 1
Completed
- Conditions
- Muscle Anabolism
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00812396
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 63
- Registration Number
- NCT00811642
Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)
Phase 3
Terminated
- Conditions
- Hepatitis C, ChronicLiver Cirrhosis
- Interventions
- Biological: PegIntron (peginterferon alfa-2b; SCH 54031)Drug: Rebetol (ribavirin; SCH 18908)
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00811967
Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 252
- Registration Number
- NCT00811928
Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects
Phase 1
Completed
- Conditions
- Chronic Hepatitis C (HCV)
- Interventions
- Drug: IDX184
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00807001
© Copyright 2025. All Rights Reserved by MedPath